ResMed/$RMD
1D1W1MYTD1Y5YMAX
Capital at risk
About ResMed
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks, and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea, combined with aging populations and increasing prevalence of obesity, is resulting in a structurally growing market. The company earns roughly two-thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan, and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor, and payer in the out-of-hospital setting.
- Ticker
- $RMD
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 11,370
- Headquarters
- San Diego, United States
- Website
- www.resmed.com
ResMed Metrics
BasicAdvanced
$33B
22.00
$10.43
0.77
$2.40
1.05%
Price and volume
Market cap
$33B
Beta
0.77
52-week high
$284.87
52-week low
$180.27
Average daily volume
1.5M
Dividend rate
$2.40
Financial strength
Current ratio
3.1
Quick ratio
1.831
Long term debt to equity
0.082
Total debt to equity
0.125
Dividend payout ratio (TTM)
22.95%
Profitability
EBITDA (TTM)
2,095.775
Gross margin (TTM)
61.62%
Net profit margin (TTM)
26.94%
Operating margin (TTM)
33.96%
Effective tax rate (TTM)
20.64%
Revenue per employee (TTM)
$500,000
Management effectiveness
Return on assets (TTM)
14.00%
Return on equity (TTM)
24.27%
Valuation
Price to earnings (TTM)
21.998
Price to revenue (TTM)
5.906
Price to book
5.03
Price to tangible book (TTM)
10.27
Price to free cash flow (TTM)
20.501
Free cash flow yield (TTM)
4.88%
Free cash flow per share (TTM)
11.192
Dividend yield (TTM)
1.05%
Forward dividend yield
1.05%
Growth
Revenue change (TTM)
9.85%
Earnings per share change (TTM)
9.67%
3-year revenue growth (CAGR)
10.21%
10-year revenue growth (CAGR)
11.89%
3-year earnings per share growth (CAGR)
19.64%
10-year earnings per share growth (CAGR)
15.40%
3-year dividend per share growth (CAGR)
10.89%
10-year dividend per share growth (CAGR)
6.91%
What the Analysts think about ResMed
Analyst ratings (Buy, Hold, Sell) for ResMed stock.
Analyst projections of the future price of ResMed stock.
Bulls say / Bears say
Full-year FY2026 revenue rose 9.85% to $5.65 billion, driven by robust demand across Sleep and Breathing Health and Residential Care Software segments, underpinning ResMed’s market leadership in respiratory care (FT)
ResMed completed its $340 million acquisition of Noctrix Health, adding FDA De Novo–classified wearable therapeutics for Restless Legs Syndrome and expected to contribute about $30 million in FY27 revenue, diversifying its digital health portfolio (Reuters)
ResMed agreed to sell its non-core MatrixCare software business for $490 million in cash, sharpening its focus on core sleep and home health solutions while bolstering capital for strategic investments and shareholder returns (Reuters)
Shares of ResMed dropped about 6% after management guided fiscal 2027 revenue below Wall Street expectations, signaling investor concern over a slowdown in growth momentum (Reuters)
ResMed suspended new Astral ventilator sales globally following a field safety action, creating a material headwind to FY27 revenue and highlighting operational and regulatory risks (Reuters)
The sale of the MatrixCare business divests a segment that generated approximately $220 million in revenue and $55 million in adjusted operating profit in FY26, potentially reducing recurring software revenue and long-term revenue diversification (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 3 Sept 2026.
ResMed Financial Performance
Revenues and expenses
ResMed Earnings Performance
Company profitability
Upcoming events
ResMed News
AllArticlesVideos
Funds containing ResMed
AllEURGBPUSD
Fund name | Fund size | $RMD weighting |
|---|---|---|
iShares S&P 500 Health Care Sector€IUHE | €125M | 0.53% |
iShares MSCI World Health Care Sector Advanced€CBUF | €606M | 0.43% |
iShares S&P 500 Equal Weight€O4J0 | €4.3B | 0.22% |
iShares S&P 500 Equal Weight£EWSP | £3.7B | 0.22% |
iShares MSCI USA Islamic$ISDU | $594M | 0.19% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.